Managed Healthcare Executive5h
Entrada Therapeutics On Track For New DMD Study in the U.K.
Managed Healthcare Executive provides C-suite executives at health plans and provider organizations with news, analysis, ...
Monthly Prescribing Reference7h
Troculeucel Gets Fast Track Status for Moderate Alzheimer Disease
The Fast Track designation is supported by data from the open-label phase 1 SNK01-MX04 trial, as well as preliminary data from the phase 1 cohort from the phase 1/2a SNK01-AD01 trial.
FierceBiotech10h
Biogen axes asset from $7.3B buyout, along with Alzheimer’s and Parkinson’s prospects
BIIB143, also known as cemdomespib, was the most advanced asset to get the chop. Biogen acquired the Hsp90 modulator in 2023 through its buyout of Reata, a deal that centered on the FDA-approved ...
Aptose’s Frontline Triple Drug Therapy with Tuspetinib Achieves Notable Responses in Newly Diagnosed AML Patients in the Phase 1/2 TUSCANY Trial
In January 2025, Aptose announced the initiation of the TUSCANY trial and dosing in the first cohort of newly-diagnosed AML patients with the lowest starting dose (40 mg) of TUS as part of the ...
Arvinas Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Corporate Update
Announced that topline data from the monotherapy Phase 3 VERITAC-2 trial isanticipated in 1Q25 –– Presented Phase 1b data from the TACTIVE-U ...
Novo Nordisk's new CagriSema obesity drug trial to begin on Feb. 10, clinicaltrials.gov entry shows
Novo Nordisk will begin a new late-stage trial of its experimental next-generation obesity drug CagriSema on Feb. 10, ...
Novo Nordisk will test CagriSema's long-term efficacy in late-stage trial, clinicaltrials.gov entry shows
Novo Nordisk will begin a late-stage trial of its experimental next-generation obesity drug CagriSema on Feb. 10 to test its ...
pulmonologyadvisor1d
Sotatercept Trial Ends Due to Positive Clinical Program Efficacy Data
The HYPERION study will be stopped early due to positive efficacy data from across the sotatercept clinical program.
Renal & Urology News1d
Gamma Delta CAR T-Cell Therapy Fast Tracked for SLE With Extrarenal Involvement
The FDA has granted Fast Track designation to ADI-001 for the treatment of refractory systemic lupus erythematosus with extrarenal involvement.
Medscape1d
Underfunded, Underdiagnosed, and Misunderstood: What’s Next for Bipolar Disorder
BD affects millions but remains misunderstood, underdiagnosed, and underfunded. Researchers are working to change this by ...
clinicalpainadvisor.com5d
FDA Drug Approval Decisions Expected in March 2025
The Prescription Drug User Fee Act (PDUFA) date refers to the deadline set by the US Food and Drug Administration (FDA) for ...
JD Supra15d
Clinicaltrials.gov: Recent Action May Signal Increased Attention from FDA on Trial Data Reporting Compliance
The US Food and Drug Administration (FDA) recently issued a notice of noncompliance to the FADOI Foundation, citing the organization’s failure ...